Clopidogrel (clopidogrel bisulfate) NDC 68788-4173

NDC codes

FDA NDC Directory

Product NDC (as listed)68788-4173Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68788-4173Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
68788-4173-3	68788417303	30 TABLET, FILM COATED in 1 BOTTLE (68788-4173-3)Marketed from Jul 24, 2026
68788-4173-6	68788417306	60 TABLET, FILM COATED in 1 BOTTLE (68788-4173-6)Marketed from Jul 24, 2026
68788-4173-9	68788417309	90 TABLET, FILM COATED in 1 BOTTLE (68788-4173-9)Marketed from Jul 24, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clopidogrel
Generic name (nonproprietary): clopidogrel bisulfate
Active ingredients: Clopidogrel bisulfate — 75 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Preferred Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215388
Marketing start: Jul 24, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C8 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 68788-4173_c9928956-bb7b-4ec2-bc38-d3c9c4199caeSPL ID c9928956-bb7b-4ec2-bc38-d3c9c4199caeSPL set ID c9928956-bb7b-4ec2-bc38-d3c9c4199caeRxCUI 309362UNII 08I79HTP27
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468788417303 followed by a unit qualifier and the quantity

Package 68788-4173-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 24, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) – For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets are indicated to reduce the ra…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215388

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215388
Product	Strength	Form · route	Labeler	Product NDC
Clopidogrelclopidogrel bisulfate	Clopidogrel bisulfate 75 mg/1	Tablet, Film coatedOral	Novadoz Pharmaceuticals LLC	72205-199